In 2012, USPTF downgraded PSA testing without adequate stakeholder engagement or a full understanding of the peer-reviewed clinical literature. That opaque and ill-informed process led to tens of thousands of fewer men being identified with prostate cancer and a substantial increase in the number of men later identified with higher risk, more advanced prostate cancer where treatment was less effective. While USPTF has recently changed its rating for certain demographics of men, the process remains non-transparent and the task force deliberations and decisions are not subject to notice and comment rulemaking or consultation with stakeholders. LUGPA supports legislation to provide greater transparency and accountability of the USPTF.
What is LUGPA’s Goal?
LUGPA firmly believes that in order to optimize patient–physician shared decision-making for both diagnosis and treatment of prostate cancer, healthcare providers should have the ability to counsel patients upon evidence based best practices that consider the individual patient’s specific medical condition and needs.